According to MHT, Stem cell research company Stemgent Inc. has taken $11.3 million in equity, the largest round to date for the four-and-a-half year old company. According to SEC filings, the 40-plus employee company, has filed for more than $40 million in debt and equity investment to date.

Stemgent, Inc. is engaged in working alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions for the advancement of stem cell research. The firm's mission is to help simplify and support cellular reprogramming research by producing products being designed by leading stem cell researchers worldwide. Stemgent's scientific development sites are located in both Cambridge, Massachusetts and San Diego, California.